Full text is available at the source.
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
Urinary and genital infections linked to diabetes drugs that lower blood sugar by removing sugar through urine: A combined analysis of clinical trials
AI simplified
Abstract
A total of 52 randomized controlled trials involving 36,689 patients were analyzed for the effects of SGLT2 inhibitors on infection risks.
- Canagliflozin, dapagliflozin, and empagliflozin are linked to a greater risk of genital infections compared to placebo.
- Odds ratios for genital infections ranged from 3.21 for dapagliflozin 2.5 mg to 5.23 for canagliflozin 300 mg.
- Dapagliflozin 10 mg was the only treatment associated with a significantly higher risk of urinary tract infections.
- A dose-response relationship for increased risk of UTIs and genital infections was observed specifically with dapagliflozin.
- No significant factors were identified that modified the risk of these infections in the meta-regression analysis.
AI simplified